For instance, several recent meta-analysis studies reported that ESA administrations, while reducing the incidence of clinically defined anemia, may confer an adverse survival to patients exhibiting a large change in Hb levels during treatment[9-12]. This evidence concerns the gene GSTM1 and anemia (phenotype).